Company intelligence / Profile preview

NeuroFlex

Huntington Beach, California, United Statesneuroflex.io ↗

Ownership: Private
Development stage: Preclinical

Overview

Over 19,500 tests conducted with more than one million individual data points collected. The device provides objective quantitative metrics to support clinical decision-making but does not itself provide a diagnosis. It has received regulatory registration from the FDA, TGA (Australia), EMA (Europe), MHRA (UK), Health Canada & South Africa HPRA.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapySoftware
Industry: Physiological Monitoring

Partnerships

Australian pharmacy chains piloting concussion screening using NeuroFlex technologyPossible collaboration with Saccade Analytics for saccadic eye movement analysis

Beyond the preview

Go deeper on NeuroFlex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroFlex.

Explore the full profile